Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma.

Philipp K. Haber,Miguel Torres-Martin,Jean-François Dufour,Chris Verslype,Jens U. Marquardt,Peter R. Galle,Arndt Vogel,Tim Meyer,Ismail Labgaa,Lewis R. Roberts,Beatriz Minguez,Vincenzo Mazzaferro,Fabian Finkelmeier,Tobias Müller,Moritz Schmelzle,Richard S. Finn,Swan N. Thung,Augusto Villanueva,Daniela Sia,Josep M. Llovet

Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma.

2021

4100Background: Checkpoint inhibition with anti-PD1 is able to elicit objective response rates (ORR) of 20% in patients with advanced hepatocellular carcinoma (aHCC) but molecular biomarkers pred...

Keywords:

Hepatocellular carcinoma
objective response
Medicine
in patient
Cancer research
anti pd1
molecular biomarkers
immune checkpoint inhibitors

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations